تحميل
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
1.93 US$
−0.02 US$ · -1.03%
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.
الإغلاق السابق
1.93 US$
−0.02 US$ · -1.03%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.
نطاق اليوم
السعر الحالي 1.93 US$
نطاق 52 أسبوعًا
السعر الحالي 1.93 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
بيع
تقييم
28
مرتفع السعر
المشاعر
43
مختلط
المخاطر
75
مخاطر مرتفعة
الزخم
50
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.
نطاق اليوم
السعر الحالي 1.93 US$
نطاق 52 أسبوعًا
السعر الحالي 1.93 US$
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| البحث والتطوير | 142.67 مليون USD | 97.2 مليون USD | 55.42 مليون USD | 39.3 مليون USD | 32.49 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 29.57 مليون USD | 27.94 مليون USD | 19.24 مليون USD | 14.84 مليون USD | 13.82 مليون USD |
| نفقات التشغيل | 172.24 مليون USD | 125.14 مليون USD | 74.66 مليون USD | 54.14 مليون USD | 46.31 مليون USD |
| دخل الفوائد | 6.03 مليون USD | 10.03 مليون USD | 6.99 مليون USD | 1.16 مليون USD | 24 ألف USD |
| مصاريف الفوائد | 2 مليون USD | 748 ألف USD | — | — | — |
| الاستهلاك والإطفاء | 1.65 مليون USD | 1.71 مليون USD | 1.43 مليون USD | 1.18 مليون USD | 733 ألف USD |
| الدخل التشغيلي | −172.24 مليون USD | −125.14 مليون USD | −74.66 مليون USD | −54.14 مليون USD | −46.31 مليون USD |
| صافي الدخل | −167.86 مليون USD | −115.86 مليون USD | −67.68 مليون USD | −52.98 مليون USD | −46.29 مليون USD |
تم تحديث حقائق الشركة 10 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI16.22 مليون0.00%2.3 ترليون USD0.03%381.94 US$+0.63%
State Street SPDR S&P Biotech ETFXBI9.77 مليون0.10%9.87 مليار USD0.35%153.77 US$+3.00%
iShares Russell 2000 ETFIWM8.37 مليون0.01%78.27 مليار USD0.19%278.94 US$+0.49%
Vanguard Extended Market ETFVXF5.91 مليون0.01%95.4 مليار USD0.05%235 US$+0.80%
Fidelity Enhanced Small Cap ETFFESM3.45 مليون0.05%6.41 مليار USD0.28%45.46 US$+0.46%
iShares Biotechnology ETFIBB2.22 مليون0.02%10.28 مليار USD0.44%206.49 US$+3.00%
Vanguard Russell 2000 ETFVTWO2.01 مليون0.01%18 مليار USD0.06%112.66 US$+0.50%
iShares Russell 2000 Growth ETFIWO1.5 مليون0.01%13.97 مليار USD0.24%356.78 US$+0.94%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
